Hydrocodone/acetaminophen

Limits on what this shows

• Null findings: A PubMed listing search for "hydrocodone mitochondrial" returned a 404 page, which PubMed gives when a query has no matching records (a broader OR phrasing was rate-limited and not retried). No therapeutic-dose mitochondrial measurement for acetaminophen was found.

Ingredient

Acetaminophen (overdose). Hydrocodone: no data.

Direction

Excess toxicity (the drug's own overdose injury). Not a nutrient deficiency (Hard Rule 2).

Regulatory status

No mitochondrial statement; hepatotoxicity warning only [1].

Population evidence

McGill 2012 [8] (Tier A for the overdose population; abstract read via OpenAlex): plasma glutamate dehydrogenase (a mitochondrial damage marker) and mitochondrial DNA fragments were measured in acetaminophen-overdose patients with varying injury severity and in healthy controls, with peak levels tracking abnormal liver tests; mouse experiments agreed. The abstract's counts and magnitudes were not retrieved. Pharmacology reference [4]: reactive-metabolite protein adducts alter the mitochondrial ATP synthase alpha subunit and generate mitochondrial nitrotyrosine adducts. Two further records were seen as metadata only and not used: a HepG2 human-cell study of mitochondrial ROS and electron transport gene expression [9] and a handbook review of mechanisms of acetaminophen liver necrosis [10].

Mechanism

Named for overdose: reactive metabolite binding to mitochondrial proteins, then mitochondrial dysfunction and DNA fragmentation [4][8].

Counter-evidence held on record

Counter-evidence Evidence is from overdose, where glutathione is exhausted; it does not show mitochondrial harm at labeled doses. Hydrocodone is wholly unstudied here. Framing caution Not a deficiency claim and not an expected therapeutic effect. Do not use this entry to suggest mitochondrial supplements.

Limits on what this shows

• Null and contrary findings: Janz 2013 [7] (Tier B/C, acetaminophen alone, observational, 391 critically ill patients): in sepsis, acetaminophen use was associated with lower plasma F2-isoprostanes (18.5 versus 42 pg/mL, P = 0.009) and lower mortality odds (OR 0.48, P = 0.026), the opposite direction for a lipid peroxidation marker, in a hemoprotein-rich setting and with confounding by indication. The label-level hepatic safety of therapeutic dosing is not contradicted by a small blood GSH change.
• At-risk subgroups: From the pharmacology reference: fasting or malnutrition, chronic alcohol use, older age and low glutathione stores increase the chance that glutathione becomes limiting [4]. These are context for toxicity risk, not findings from the trial.

Ingredient

Acetaminophen. Hydrocodone was not in the cohort.

Direction

Depletion (consumption of an endogenous antioxidant by conjugation-driven loss, mechanism class E).

Regulatory status

The label states that part of acetaminophen is oxidized by the cytochrome P450 pathway "to form a reactive intermediate metabolite, which conjugates with glutathione" and that dose-dependent hepatic necrosis is the most serious adverse effect of overdosage [1]. No glutathione depletion warning at therapeutic dose appears in the text read.

Population evidence

Pickering 2018/2019 [5] (Tier A, abstract read via a reconstructed OpenAlex abstract; full text not opened): randomized, double-blind controlled trial (NCT02206178), 24 healthy volunteers. NAC or placebo for four days (1 g four times daily), then oral acetaminophen with NAC or placebo; whole-blood GSH, ASAT and ALAT measured at day 0 and day 4. GSH stayed at baseline in the acetaminophen plus NAC group and decreased in the acetaminophen plus placebo group (P = 0.033). The abstract does not give the acetaminophen dose, the arm sizes, the magnitude of the fall, or the transaminase result. Supporting title only: Lauterburg and Mitchell 1987 [6] ("Therapeutic doses of acetaminophen stimulate the turnover of cysteine and glutathione in man"); its abstract could not be retrieved, so it is not used for grading.

Mechanism

Named. Reactive-metabolite formation by CYP2E1 and related enzymes, then glutathione conjugation [1][4]. In overdose, glutathione stores are exhausted and hepatocellular necrosis follows [4]; that overdose injury is the drug's own toxicity.

Boundary

Short exposure, healthy volunteers, functional blood marker, one trial, abstract-level read, ingredient tested alone.

Counter-evidence held on record

Counter-evidence and confounding The trial is small, the clinical meaning of a modest blood GSH decrease is not shown, and no liver injury at therapeutic dose is claimed here. Glutathione is synthesized by the body and has no recommended dietary intake. Janz 2013 [7] runs the other way for a lipid peroxidation marker. Framing caution This is an acetaminophen-ingredient finding in healthy volunteers over a short window, not a claim that hydrocodone/acetaminophen depletes antioxidants in ordinary use. Do not recommend glutathione or N-acetylcysteine supplements from this entry; N-acetylcysteine is an overdose antidote used under medical care. No supplement dose is given or implied. Overdose liver injury is drug toxicity, not a nutrient deficiency (Hard Rule 2).

Limits on what this shows

• Null findings: A PubMed search combining hydrocodone with iron, copper, ferritin and anemia returned 20 unrelated iron-diagnosis and treatment papers and none about hydrocodone. No human study of acetaminophen and serum iron or ferritin was located.

Ingredient

Acetaminophen (in vitro, mouse). Hydrocodone: no data.

Direction

Excess or redistribution of labile intracellular iron during toxicity. Not depletion. Supplementation would be the hazard, not the remedy.

Regulatory status

No iron statement in the label text read [1].

Population evidence

None in humans. Gong 2025 [12] (Tier B; abstract read via OpenAlex): primary mouse hepatocytes exposed to 20 mM acetaminophen showed GSH depletion, mitochondrial dysfunction, iron-dependent lipid peroxidation, ferritin degradation and iron release; the iron chelator deferoxamine and N-acetylcysteine reduced the toxicity. A second ferritinophagy paper (Toxicol Appl Pharmacol 2025) was seen only as metadata and is not used.

Mechanism

Named for toxicity: oxidant damage to ferritin releases iron that amplifies lipid peroxidation [12].

Counter-evidence held on record

Counter-evidence 20 mM is far above therapeutic exposure, the model is mouse cells, and redistribution of intracellular iron is not systemic iron deficiency or overload. Framing caution Not an iron deficiency claim and not a reason to take iron. Anemia is not iron deficiency (Hard Rule 2).

Limits on what this shows

• Null findings: A PubMed search for acetaminophen with serum iron, ferritin, serum copper or ceruloplasmin returned 20 records, none showing an acetaminophen effect on copper status; the combined hydrocodone iron or copper search found nothing for hydrocodone.

Ingredient

Acetaminophen (in vitro). Hydrocodone: no data.

Direction

Neutral for status. The documented relationship is copper affecting the drug's pro-oxidant chemistry, not the drug depleting copper (Hard Rule 4).

Regulatory status

No copper statement in the label text read [1].

Population evidence

None in humans. Li and Trush 1994 [13] (Tier B, in vitro; abstract read via OpenAlex): in the presence of micromolar Cu(II), a series of phenolic compounds including acetaminophen caused strand breaks in phi X-174 DNA; compounds with a single phenol group, such as acetaminophen, were least reactive; the damage was inhibited by a Cu(I)-specific chelator and by catalase, pointing to Cu(II)/Cu(I) redox cycling and hydrogen peroxide. Other PubMed hits (animal studies of copper modulating acetaminophen hepatotoxicity) were listing titles only and were not opened.

Mechanism

Demonstrated in vitro as copper redox cycling. No mechanism by which the drug lowers or raises body copper was found.

Counter-evidence held on record

Counter-evidence In vitro DNA cleavage in a test tube with added copper is not evidence of depletion, excess or harm in people. Framing caution Mechanistic curiosity only. Not a deficiency claim and not a reason to take or avoid copper. Kept separate from Iron (Hard Rule 7).

Limits on what this shows

• Null findings: PubMed searches for "hydrocodone microbiota" and "opioid gut microbiome humans hydrocodone" returned either an unrelated mouse study or no records. Most acetaminophen-microbiome records found ran the other direction (microbiota modulating acetaminophen liver injury), which is not a drug effect on the microbiome (Hard Rule 4).

Ingredient

Hydrocodone (via opioid class). Acetaminophen: marginal, prenatal only.

Direction

Composition change (neutral to adverse). Not a nutrient deficiency.

Regulatory status

Label states propulsive peristaltic waves in the colon are decreased and tone may rise to spasm, resulting in constipation; anticholinergics add risk of severe constipation [1]. No microbiome statement.

Population evidence

CLASS EXTRAPOLATION. Le Bastard 2017/2018 [15] (systematic review, abstract read; Tier C): opioids were associated with an increase in alpha diversity and, with other drug classes, with increases in Gammaproteobacteria or Enterococcaceae; individual opioids were not named in the abstract. Acharya 2016/2017 [16] (Tier C; abstract read): 200 hospitalized cirrhotic patients with or without chronic opioid use; in 72 matched participants, opioid users had reduced Bacteroidaceae and higher endotoxin and aromatic amino acid production, with elevated IL-6 and IL-17; hydrocodone was not named in the abstract, and the cirrhosis population is heavily confounded. Coluzzi 2024 [17] (narrative review, Tier C): opioid effects on microbiota are discussed in general terms with no specific opioids named. Laue 2022 [18] (Tier B/C; prenatal cohort, abstract read): fecal acetaminophen exposure showed a trend toward lower bacterial diversity and marginal phylum differences in infants, a different population and exposure window.

Mechanism

Plausible: slowed transit and altered motility (label [1]). Not demonstrated for hydrocodone.

Class cohort test

Hydrocodone was not documented in the cohort of any microbiome study opened; full texts were not opened, so a named subgroup cannot be excluded. Capped at yellow. The morphine animal literature surfaced in the listing was not used.

Counter-evidence held on record

Counter-evidence The increase in alpha diversity in the systematic review [15] is counterintuitive for "dysbiosis" and shows the direction is not settled. Cirrhosis and constipation itself are confounders. Framing caution Not a claim of dysbiosis from hydrocodone/acetaminophen. Constipation is a motility effect listed in the label, not a deficiency.

Limits on what this shows

• Null findings: No hydrocodone ATP or energy-output record located (same 404 no-match PubMed search as the mitochondrial entry). No circulating "low energy" claim specific to this product was found.

Ingredient

Acetaminophen (overdose). Hydrocodone: no data.

Direction

Excess toxicity. Not a nutrient deficiency (Hard Rule 2).

Regulatory status

No ATP or energy-metabolism statement in the label text read [1].

Population evidence

None in humans measuring ATP. The pharmacology reference [4] states that adduct-driven mitochondrial injury ends in "halting ATP synthesis" in the necrosis cascade (Tier B, mechanistic reference). A PubMed listing for acetaminophen, hepatocyte ATP depletion and mitochondria returned many animal and cell studies (including primary hepatocyte and human-cell work); these were seen only as listing titles and gists, and none was opened, so none is cited as evidence.

Mechanism

Named for overdose [4]. Not shown at therapeutic dose.

Counter-evidence held on record

Counter-evidence Cellular ATP loss in overdose models is a consequence of necrosis-pathway injury and does not imply reduced energy output in someone taking labeled doses. Framing caution Kept independent of Mitochondrial burden and Oxygen delivery/utilization (Hard Rule 7) but not independent evidence (see Overlap map). Not a fatigue explanation.

Limits on what this shows

• Null findings: No hemoglobin, hematocrit or red-cell-mass study of hydrocodone was found (the combined hydrocodone iron, ferritin and anemia search returned nothing on hydrocodone). Iron or B12 pathways to anemia were not found for this product.

Ingredient

Acetaminophen (case series). Hydrocodone (respiratory depression, label only).

Direction

Drug adverse effect or toxicity. Not a nutrient deficiency (Hard Rule 2).

Regulatory status

Label warns that interactions with CYP3A4 inhibitors and with benzodiazepines can cause potentially fatal respiratory depression and profound sedation [1]. No methemoglobinemia statement in the text read.

Population evidence

Sahu 2020 [11] (systematic review of case reports, 1968 to 2019; Tier B; abstract read via OpenAlex): 14 cases of acetaminophen-associated methemoglobinemia (the abstract's own sex counts, 9 female and 6 male, sum to 15); median age 59; intent therapeutic in 7 and suicidal in 5; the dose was unknown in most; other agents co-ingested included aspirin, sulfasalazine, benzocaine spray, a nitrate preservative and contaminated water; median methemoglobin 15.85%; 10 recovered and 4 died. A PubMed listing on G6PD deficiency and paracetamol hemolysis surfaced case reports of hemolysis after overdose and one prospective pediatric study and one controlled trial reporting no hemolysis at therapeutic doses; these were titles and gists only and are not used (abstract of the pediatric record could not be retrieved).

Mechanism

Not established in the abstract read. Respiratory depression by hydrocodone is the intended class pharmacology of an opioid agonist at excess exposure, and hypoventilation is not oxygen-delivery nutrient deficiency; it is written up here as a mechanism clarification only.

Counter-evidence held on record

Counter-evidence Methemoglobinemia was seen with co-ingestants and mostly with poisoning or unknown doses; it is rare. No therapeutic-dose hemoglobin effect was shown. Framing caution Not a deficiency claim. Anemia is an outcome, not a nutrient. Respiratory depression is a labeled drug risk handled by prescribers, not by supplements.